File Download
Supplementary

Conference Paper: Diagnostic Significance of Exosomal miRNAs in the Plasma of Breast Cancer Patients

TitleDiagnostic Significance of Exosomal miRNAs in the Plasma of Breast Cancer Patients
Authors
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerres.aacrjournals.org/
Citation
34th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011. In Cancer Research, v. 71 n. 24 How to Cite?
AbstractBackground and Aims: Emerging evidence that microRNAs (miRNAs) play an important role in cancer development has opened up new opportunities for cancer diagnosis. Recent studies demonstrated that released exosomes which contain a subset of both cellular mRNA and miRNA could be a useful source of biomarkers for cancer detection. Here, we aim to develop a novel biomarker for breast cancer diagnosis using exosomal miRNAs in plasma. Methods: We have developed a rapid and novel isolation protocol to enrich tumor-associated exosomes from plasma samples by capturing tumor specific surface markers containing exosomes. After enrichment, we performed miRNA profiling on four sample sets; (1) Ep-CAM marker enriched plasma exosomes of breast cancer patients; (2) breast tumors of the same patients; (3) adjacent non-cancerous tissues of the same patients; (4) Ep-CAM marker enriched plasma exosomes of normal control subjects. Profiling is performed using PCR-based array with human microRNA panels that contain more than 700 miRNAs. Results: Our profiling data showed that 15 miRNAs are concordantly up-regulated and 13 miRNAs are concordantly down-regulated in both plasma exosomes and corresponding tumors. These account for 25% (up-regulation) and 15% (down-regulation) of all miRNAs detectable in plasma exosomes. Our findings demonstrate that miRNA profile in EpCAM-enriched plasma exosomes from breast cancer patients exhibit certain similar pattern to that in the corresponding tumors. Based on our profiling results, plasma signatures that differentiated breast cancer from control are generated and some of the well-known breast cancer related miRNAs such as miR-10b, miR-21, miR-155 and miR-145 are included in our panel list. The putative miRNA biomarkers are validated on plasma samples from an independent cohort from more than 100 cancer patients. Further validation of the selected markers is likely to offer an accurate, noninvasive and specific diagnostic assay for breast cancer. Conclusions: These results suggest that exosomal miRNAs in plasma may be a novel biomarker for breast cancer diagnosis.
DescriptionAbstract no. P4-08-05
Persistent Identifierhttp://hdl.handle.net/10722/196734
ISSN
2015 Impact Factor: 8.556
2015 SCImago Journal Rankings: 5.372

 

DC FieldValueLanguage
dc.contributor.authorKwong, A-
dc.contributor.authorNg, EKO-
dc.contributor.authorLeung, CPH-
dc.contributor.authorChan, V-
dc.contributor.authorLi, R-
dc.contributor.authorWong, CLP-
dc.contributor.authorMa, ESK-
dc.date.accessioned2014-04-25T04:47:52Z-
dc.date.available2014-04-25T04:47:52Z-
dc.identifier.citation34th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011. In Cancer Research, v. 71 n. 24-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/196734-
dc.descriptionAbstract no. P4-08-05-
dc.description.abstractBackground and Aims: Emerging evidence that microRNAs (miRNAs) play an important role in cancer development has opened up new opportunities for cancer diagnosis. Recent studies demonstrated that released exosomes which contain a subset of both cellular mRNA and miRNA could be a useful source of biomarkers for cancer detection. Here, we aim to develop a novel biomarker for breast cancer diagnosis using exosomal miRNAs in plasma. Methods: We have developed a rapid and novel isolation protocol to enrich tumor-associated exosomes from plasma samples by capturing tumor specific surface markers containing exosomes. After enrichment, we performed miRNA profiling on four sample sets; (1) Ep-CAM marker enriched plasma exosomes of breast cancer patients; (2) breast tumors of the same patients; (3) adjacent non-cancerous tissues of the same patients; (4) Ep-CAM marker enriched plasma exosomes of normal control subjects. Profiling is performed using PCR-based array with human microRNA panels that contain more than 700 miRNAs. Results: Our profiling data showed that 15 miRNAs are concordantly up-regulated and 13 miRNAs are concordantly down-regulated in both plasma exosomes and corresponding tumors. These account for 25% (up-regulation) and 15% (down-regulation) of all miRNAs detectable in plasma exosomes. Our findings demonstrate that miRNA profile in EpCAM-enriched plasma exosomes from breast cancer patients exhibit certain similar pattern to that in the corresponding tumors. Based on our profiling results, plasma signatures that differentiated breast cancer from control are generated and some of the well-known breast cancer related miRNAs such as miR-10b, miR-21, miR-155 and miR-145 are included in our panel list. The putative miRNA biomarkers are validated on plasma samples from an independent cohort from more than 100 cancer patients. Further validation of the selected markers is likely to offer an accurate, noninvasive and specific diagnostic assay for breast cancer. Conclusions: These results suggest that exosomal miRNAs in plasma may be a novel biomarker for breast cancer diagnosis.-
dc.languageeng-
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerres.aacrjournals.org/-
dc.relation.ispartofCancer Research-
dc.titleDiagnostic Significance of Exosomal miRNAs in the Plasma of Breast Cancer Patientsen_US
dc.typeConference_Paperen_US
dc.identifier.emailKwong, A: avakwong@hkucc.hku.hk-
dc.identifier.emailNg, EKO: ngko@hku.hk-
dc.identifier.emailChan, V: vnychana@hkucc.hku.hk-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros700001543-
dc.identifier.volume71-
dc.identifier.issue24-
dc.publisher.placeUnited States-
dc.customcontrol.immutableyiu 140425-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats